Rho Chi Post

An award-winning, electronic, student-operated newsletter publication by the St. John's University College of Pharmacy and Health Sciences Rho Chi Beta Delta chapter

Menu

Skip to content
  • Home
  • Issues
    • Current Issue
    • All Issues
  • Articles
    • Featured
    • In the News / Politics
    • Events
    • Clinical
    • Advice / Opinions
    • Puzzles
    • Recently in PubMed
  • For Authors
    • Author Guidelines
    • AMA Citation Generator
    • Sign Up for Article(s)
    • Suggest Article(s)
    • Submit Article(s)
    • Check Statuses
    • Cite Your Article
  • About Us
    • About the Rho Chi Post
    • The Editorial Team
  • Apply for a Position
  • Subscribe
  • Login

Basal-bolus vs. sliding-scale insulin in hospitalized patients: assessment of advantages and disadvantages

By:  Maria Sedky Saad (PharmD Candidate c/o 2021), Shivani Shah (PharmD Candidate c/o 2021)            Hyperglycemia is a common condition in hospitalized patients whose glucose levels are normally controlled with oral antidiabetic medications, which are often discontinued upon admission. To circumvent hyperglycemic complications in hospitalized patients with type 1 and type 2 diabetes, glucose levels…

Continue reading →

Treatment of iron deficiency anemia

By: Maryam Sekhery, PharmD Candidate c/o 2020            According to the World Health Organization, anemia is defined as having a level of Hemoglobin (Hb) below 13.0 g/dL in male adults, below 12.0 g/dL in female adults who are not pregnant, and below 11.0 g/dL in pregnant women.1 Hemoglobin is an iron-containing oxygen-transport metalloprotein in red…

Continue reading →

FDA approves romosozumab (Evenity®) for the treatment of postmenopausal osteoporosis

By: Michael Lim, PharmD Candidate c/o 2020            Osteoporosis is a bone disease affecting nearly ten million people in the United States.1 It can be caused by excess bone loss, insufficient bone production, or a combination of both factors. The disease is responsible for two million broken bones and 19 billion dollars in related healthcare…

Continue reading →

Residency Starter Guide

By: Yao Jiang, PharmD (St. John’s University c/o 2019)            “Do you want to do a residency?” a senior pharmacy student asked me as I strolled past their booth on Pharmacy Organization Day during my first year of pharmacy school. I stopped for a minute, but everything they said about post graduate training and clinical…

Continue reading →

Food and Drug Administration approves lofexidine (LucemyraTM): the first non-addictive opioid withdrawal therapy in the United States

By: Evanthia Siozios, PharmD Candidate c/o 2020            Anxiety, nausea, muscle pain, insomnia are some of the most common withdrawal symptoms experienced when users stop taking opioids. According to a randomized controlled trial entitled Prescription Opioid Addiction Treatment Study (POATS) conducted in outpatient treatment settings across the United States including Mclean Hospital in Massachusetts and…

Continue reading →

(Volume 9, Issue 2)
Basal-bolus vs. sliding-scale insulin in hospitalized patients: assessment of advantages and disadvantages

FDA approves romosozumab (Evenity®) for the treatment of postmenopausal osteoporosis

Treatment of iron deficiency anemia

View Full Issue

Do You Want to be a Published Author? Submit your Article(s) Today!


 Tweets by @RhoChiPost
HOME: Home Page

ISSUES: Volume 9 . Volume 8 . Volume 7 . Volume 6 . Volume 5 . Volume 4 . Volume 3 . Volume 2 . Volume 1

ARTICLES: Featured . In the News / Politics . Events . Clinical . Advice / Opinions . Puzzles

FOR AUTHORS: Guidelines . Writing Deadlines . AMA Citation Generator . Sign Up . Suggest . Submit . Cite

ABOUT US: About the Rho Chi Post . The Editorial Team . Apply for a Position

SUBSCRIBE: Google Groups Email List

Translate:
Copyright © 2011-2020 Rho Chi Post